Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Transplant outcomes in patients over 40 years old with severe aplastic anemia (SAA) treated after 2010

Retrospective Studies

Bone marrow failure

Severe Aplastic Anaemia Working Party (SAAWP)

Type of treatment

Principal investigator

Antonio Risitano

Résultats de la greffe chez les patients atteints d'aplasie médullaire sévère (SAA) âgés de plus de 40 ans et traités après 2010

Études rétrospectives

Aplasie Médullaire

Severe Aplastic Anaemia Working Party (SAAWP)

Type of treatment

Principal investigator

Antonio Risitano

Allogeneic Hematopoietic Stem Cell Transplantation for ERCC6L2 disease

Closed Survey/Study

Bone marrow failure

Severe Aplastic Anaemia Working Party (SAAWP)

Type of treatment

Principal investigator

Ulla Wartiovaara-Kautto, Outi Kilpivaara and Flore Sicre de Fontbrune

Allogeneic HSCT in ICU setting

Closed Survey/Study

Bone marrow failure

Severe Aplastic Anaemia Working Party (SAAWP)

Type of treatment

Principal investigator

Tayfun Güngör

Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone: A Retrospective Study on Behalf of the CTIWP

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Acute Myeloid Leukaemia (AML)

Chronic Lymphocytic Leukaemia (CLL)

Chronic Myeloid Leukaemia (CML)

Chronic Lymphocytic Leukaemia (CLL)

Myelodysplastic (MDS) or MDS/MPN

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Allogeneic - Haploidentical

Principal investigator

Impact of body mass index on outcome of CART cell therapy

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Christian Schultze-Florey

Efficacy and outcomes of allogeneic hematopoietic stem cell boost in adult patients with poor graft function

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Tatiana Rudakova

Outcomes of Allogeneic Hematopoietic Cell Transplantation from ≤8/10-HLA matched unrelated donor

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

GVHD Prophylaxis with ATG or PTCy after alloSCT from unrelated donors

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

ATG in the MSD setting - a real-world evidence study based on the EBMT Registry

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Agnieszka Piekarska

Survey on the use of SGLT2 inhibitors in cell therapy including autologous and allogeneic hematopoietic stem cell transplantation and CART cell therapy

Closed Survey/Study

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Christian Schultze-Florey

How risky is a second allo? A retrospective analysis of treatment-related mortality in patients receiving allogeneic stem cell transplantation for the second time

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator